Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ayala Pharmaceuticals Inc ADXS

Healthcare Biotechnology
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia... see more

Recent & Breaking News (PINL:ADXS)

Advaxis Truly Personalized Cancer Immunotherapy Moves Forward With Signing of an Exclusive Supply Agreement With Synthetic Genomics for Synthetic DNA

GlobeNewswire March 9, 2016

Dosing Begins in High Dose Expansion Cohort in Phase 2 Study of Axalimogene Filolisbac in Patients With Recurrent Cervical Cancer

GlobeNewswire March 7, 2016

Advaxis to Present at 27th Annual ROTH Conference

GlobeNewswire March 4, 2016

Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting

GlobeNewswire March 2, 2016

Advaxis to Present at Cowen's 36th Annual Health Care Conference

GlobeNewswire February 29, 2016

Advaxis to Present at 2016 RBC Capital Markets' Healthcare Conference

GlobeNewswire February 16, 2016

Advaxis to Present at 2016 RBC Capital Markets’ Healthcare Conference

Press Releases February 16, 2016

Daniel J. O'Connor, President and Chief Executive Officer of Advaxis, Appointed to Board of Trustees of BioNJ

GlobeNewswire February 8, 2016

Advaxis' Axalimogene Filolisbac to be Developed and Commercialized in Latin America With Stendhal

GlobeNewswire February 3, 2016

Advaxis Appoints Dr. Bradley Monk as Lead Cervical Cancer Advisor

GlobeNewswire February 1, 2016

Advaxis Expands Intellectual Property for Lm Technology(TM) Platform

GlobeNewswire January 19, 2016

Advaxis Provides 2016 Business Outlook

GlobeNewswire January 8, 2016

Advaxis Establishes Scientific Advisory Board With Several Distinguished Experts

GlobeNewswire January 5, 2016

FDA Lifts Advaxis Clinical Hold

GlobeNewswire December 16, 2015

Advaxis Receives Orphan Drug Designation in the European Union for Axalimogene Filolisbac for the Treatment of Anal Cancer

GlobeNewswire December 14, 2015

Advaxis to Present Poster on ADXS-HER2 at SABCS 2015

GlobeNewswire December 9, 2015

Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma

GlobeNewswire December 1, 2015

Advaxis to Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program

GlobeNewswire November 17, 2015

Advaxis Presents New Data Featuring Its Lm Technology(TM) at the Society for Immunotherapy of Cancer 2015 Annual Meeting

GlobeNewswire November 9, 2015

Advaxis to Present at the Jefferies Autumn 2015 Global Healthcare Conference

GlobeNewswire November 5, 2015